Longevity drugs · GLP-1
Tirzepatide
Dual GIP/GLP-1 agonist producing the largest average weight loss of any approved drug.
Not medical advice — talk to a licensed clinician. Content is educational, reflects published literature, and is not a recommendation to start, stop or change any treatment.
What it is
A weekly injectable approved for type 2 diabetes, obesity and obstructive sleep apnea.
How it works, in plain English
Activates both GIP and GLP-1 receptors, amplifying appetite reduction and insulin sensitivity.
What the human evidence shows
SURMOUNT-1 showed ~20% average weight loss at the highest dose. Improvements in blood pressure, lipids and sleep apnea severity. Cardiovascular outcomes trials ongoing.
Regrowth grade A: Strong human RCT evidence.
Typical protocols in the literature
Labeled titration from a low starting dose in monthly steps to a maintenance dose.
Described for education, not as dosing advice.
Side effects & interactions
Side effects
- Nausea, diarrhea
- Lean-mass loss
- Gallbladder events
Interactions
- Oral contraceptives (reduced absorption during titration)
- Insulin / sulfonylureas
Key studies
- SURMOUNT-1
- SURPASS program
- SURMOUNT-OSA
Citations pending medical review